Neoadjuvant therapy, enhanced by anti–PD-1 immunotherapy, shows promise for precision head and neck oncology, but further trials are needed to improve prediction tools. ja.ma/4nxCnO9

Approximately 21 000 women are diagnosed with ovarian cancer annually in the US. This Review summarizes the diagnosis and management of high-grade serous ovarian cancer. ja.ma/4m90xNM

🧵¿Sigue teniendo sentido ajustar el calcio total por albúmina en la práctica clínica❓Una fórmula que aprendimos todos… ¿pero sirve? 📉 🤔 ¿Seguimos enseñando y utilizando fórmulas obsoletas❓¿No es hora de actualizar nuestros protocolos y educación médica⁉️ DENTRO HILO 🪡 🧵

Revisit this 2024 review by Vivek Subbiah, MD et al which maps current FDA approvals, patient perspectives, and what’s ahead for tissue-agnostic therapies in #PrecisionOncology. 🔗 acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… OncoAlert #PrecisionMedicine

The only fantastic 4 that matters is CT neck-chest-abdomen-pelvis

Diverticulitis - new JAMA review ⭐️🔢 1️⃣ Pathophysiology ⚙️ 2️⃣ Complications ⚠️ 3️⃣ Management 💡 4️⃣ Abx for uncomplicated diverticulitis 💊 📸: jamanetwork.com/journals/jama/…

🧵 Lo que NUNCA deberíamos decirle a un paciente gravemente enfermo Una guía poderosa para mejorar nuestra comunicación clínica. Dirigido a todo el personal de salud.👇

T-DXd Retreatment After ILD (Pooled analysis – 9 trials, 2145 pts) 🔹️23% of pts with G1 ILD were retreated 🔹️ILD recurrence in 33% (all G1–2, no G5) 🔹️20% discontinued due to ILD2 🔹️75% of steroid-treated pts recovered 💥 Retreatment appears feasible with proper

FDA has published in JCO the detailed review of the adjuvant ribociclib approval based on NATALEE trial data: final iDFS, safety profile, subgroup analyses, and manufacturing process changes👇 ascopubs.org/doi/pdf/10.120…

More on genomics of NECs - nothing really new but nice lit addition nonetheless... Repeat after me: Extrapulmonary NECs are NOT SCLC (and why do we assume SCLC chemo is the best...?). APC, KRAS, BRAF and FBXW& mutations very common in colorectal NECs esmogastro.org/article/S2949-…

🎗️Oncology for The Non-Oncologist🎗️ (A practical educational series for internal medicine trainees and physicians) Episode 7: Cancer Staging Explained: What Every Non-Oncologist Should Know 📚 Listen up - 🧵

The incidence and prevalence of #melanoma, the fifth most common cancer in the US, have increased over the last 5 decades. 📌 This Review summarizes the epidemiology, pathophysiology, diagnosis, and treatment of cutaneous melanoma. 🔗 ja.ma/3UHIgeI

Finally MonarchE got OS after 7 years . It will be intresting to see magnitude of Benifit. Looking forward to the data . OncoAlert ONCO BRUNO Yakup Ergün Kate Sears

We don’t know if TNBC patients who have pCR after Keynote 522 really benefit from 9 more cycles of pembro. This trial will answer.

📘Geriatric Assessment: ASCO Global Guideline 👇 ⁦ASCO⁩ ⁦JCO Global Oncology⁩ ⁦Cristiane D Bergerot ⁦OncoAlert⁩ #cancer #oncology #MedX ascopubs.org/doi/10.1200/GO…

This paper is a nice addition to the literature on the successful use of carboplatin-paclitaxel as a radiation sensitizer. The favorable results clearly motivate larger prospective trials on the use of carbo-pac as a radiation sensitizer in HNSCC. The most commonly delivered

Dr. d.planchard at #WCLC25 with highly anticipated Presidential Plenary presentation with OS results from FLAURA2: first line chemo + osimertinib improves OS from 37.6 to 47.5m, HR 0.77, 4y OS rate 41% to 49%. Benefit seen across subgroups. Strong results - similar to MARIPOSA.

🧵 ALT vs AST :- Significance of zonation in interpreting patterns of enzyme elevations A thread 🧵-

With the increasing use of CDK4/6 inhibitors in the early setting of HR+ BC treatment, a growing proportion of patients (≈10%) will develop #resistance during or shortly after adjuvant endocrine therapy. In ESMO Open, we tried to address what we know and what we are still

Vitamin B12 for prophylaxis of capecitabine-associated hand–foot syndrome 💥Oral methylcobalamin reduced capecitabine-related HFS in HER2-negative early BC, with no added safety concerns 💬A simple prophylaxis option to support treatment adherence bmj.com/content/390/bm…